Link
Pfizer-BioNTech COVID-19 Vaccine (tozinameran) - Consumer Information
Organization: Health CanadaPublished: 2020
"This information was provided by the drug’s manufacturer when this drug product was approved for sale in Canada. It is designed for consumers and care givers. It is a summary of information about the drug and will not tell you everything about the drug. Contact your doctor or pharmacist if you have any questions about the drug." - Pfizer-BioNTech COVID-19 Vaccine (tozinameran) - Consumer Information
Resource Group:
Implementation Tool
Product Type: Guide
Research and Development
Vaccine Safety
Vaccine Ingredients
Adverse Events Following Immunization (AEFI)
Vaccine Safety
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Product Type: Guide
Category:
Vaccine Safety and Development,Research and Development,Vaccine Safety,Vaccine Ingredients,Adverse Events Following Immunization (AEFI),Vaccine Safety,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and DevelopmentResearch and Development
Vaccine Safety
Vaccine Ingredients
Adverse Events Following Immunization (AEFI)
Vaccine Safety
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Language:
English
PDFResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.